Physician

Tanvir I Qureshi, MD PC

According to 2025 Medicare claims, Tanvir Qureshi, MD PC (NPI: 1447253760) practices internal medicine in the Monroe, MI market, with the plurality of this provider's patient population coming from Monroe, MI. This provider's primary affiliated billing organization is TANVIR I QURESHI MD PC (NPI: 1730464041; TIN: 383430558) and primary practice location at 48161-3798. Qureshi is affiliated with the CCA ACO LLC (ACO ID: A2198), participating under the MSSP model.

Qureshi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 115 traditional Medicare patients, billed 881 HCPCS/CPT codes, and received $85,996 in Medicare payments. The top billing code was G0438 (Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit). Part D data shows 7,454 prescription claims across 338 beneficiaries totaling $332,693 in drug costs, led by Ozempic (Semaglutide). DME data shows 37 claims. Open Payments data shows 11 records totaling $177. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $372,247 to $85,996. Concurrently, Part D prescription costs have changed little. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $23,306 to $782.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	898	8,849	$372,247
2016	796	7,915	$299,953
2017	966	8,508	$337,566
2018	800	7,361	$277,687
2019	820	6,337	$225,368
2020	485	3,179	$170,806
2021	330	1,949	$175,828
2022	171	1,281	$122,193
2023	141	989	$97,744
2024	115	881	$85,996

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	448	11,940	$578,844
2016	422	10,920	$558,945
2017	423	11,361	$536,291
2018	378	10,065	$533,349
2019	364	8,819	$503,296
2020	361	8,915	$578,241
2021	378	8,241	$555,137
2022	364	7,621	$507,697
2023	358	7,274	$528,109
2024	338	7,454	$332,693

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	171	590	$18,662
2016	145	529	$12,400
2017	121	485	$7,422
2018	86	307	$5,706
2019	43	215	$4,751
2020	17	209	$6,100
2021	15	167	$3,746
2022	16	91	$1,179
2023	11	112	$2,288
2024	N/R	37	$367

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0438	Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit	26	26	$157
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	23	23	$123
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	104	428	$120
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	79	296	$82
71046	X-ray of chest, 2 views	31	43	$22

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	51	1,542	$51,657
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	35	1,230	$25,238
Eliquis	Apixaban	26	1,440	$22,729
Jardiance	Empagliflozin	18	1,140	$19,316
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	27	930	$13,723

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	N	N/R	14	$228
J7620	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme	N	N/R	11	$84
E0570	Nebulizer, with compressor	Y	N/R	12	$54

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	11	$177	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Tanvir I. Qureshi, MD PC?

Tedicare shows public-source Medicare data for Tanvir I. Qureshi, MD PC (NPI 1447253760), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Tanvir I. Qureshi, MD PC have ACO affiliation data?

Tanvir I. Qureshi, MD PC is shown with ACO affiliation data for CCA ACO LLC (MSSP, ACO ID A2198).

What billing organization is linked to Tanvir I. Qureshi, MD PC?

Tanvir I. Qureshi, MD PC is linked to TANVIR I QURESHI MD PC (billing NPI 1730464041) in the available physician profile data.

Does Tanvir I. Qureshi, MD PC have Open Payments data?

Tanvir I. Qureshi, MD PC has 11 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.